BridgeBio Oncology (BBOT) director Neil Kumar granted 31,675 stock options at $7.73
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics director Neil Kumar received a stock option grant for 31,675 shares of common stock at an exercise price of $7.73 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service, and expires in 2036. Following this grant, he holds 31,675 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kumar Neil
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,675 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,675 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option shares granted: 31,675 shares
Exercise price: $7.73 per share
Underlying common shares: 31,675 shares
+2 more
5 metrics
Option shares granted
31,675 shares
Stock option grant to director Neil Kumar
Exercise price
$7.73 per share
Strike price of granted stock options
Underlying common shares
31,675 shares
Common stock underlying the stock option
Post-transaction derivative holdings
31,675 derivative securities
Total options held after the grant
Option expiration date
June 15, 2036
Expiration of the granted stock options
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, underlying security, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
underlying security financial
"underlying_security_title: Common Stock"
vesting financial
"The shares underlying the stock option vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders regulatory
"the date of the next Annual Meeting of Stockholders of the Issuer"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did BridgeBio Oncology Therapeutics (BBOT) report for Neil Kumar?
Neil Kumar received a stock option grant for 31,675 shares of BridgeBio Oncology Therapeutics common stock. The award is a compensation-related option, not an open-market purchase or sale, and is reported as a derivative acquisition on Form 4.
What is the exercise price of Neil Kumar’s new BBOT stock options?
The granted stock options have an exercise price of $7.73 per share. This means Kumar can buy BridgeBio Oncology Therapeutics common stock at $7.73 once the options vest and are exercised, subject to the option’s terms and expiration date in 2036.
When do Neil Kumar’s BridgeBio Oncology Therapeutics options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. Vesting is conditioned on Kumar’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date.
When do Neil Kumar’s BBOT stock options expire?
The reported stock options have an expiration date in 2036, specifically June 15, 2036. If the options are not exercised by that expiration date, the right to purchase the 31,675 underlying shares at $7.73 per share will lapse.
How many derivative securities does Neil Kumar hold after this BBOT option grant?
Following the grant, Neil Kumar holds 31,675 derivative securities directly, corresponding to the newly awarded stock options. This figure reflects his position in this specific option award as reported in the Form 4 filing’s post-transaction holdings column.